Genmab — April 2017
-
en nyhed, der ikke omhandler dara - det vil i sandhed være en nyhed!
-
Har vi haft dette link i chatten? http://www.myelomatose.dk/content/uploads/2017/03/TorbenPlesner_Nye-behandlinger.pdf
-
Bulder..Centaurus er vist først sidst på året.
-
ALCYONE frontline MM data med Velcade kan måske nå at komme i Q2.
-
Bulder...Så har jeg ikke kunne læse mine egne kragetæer.
-
PS: Bare du dog fik ret med ALCYONE.
-
Copenhagen, Denmark; April 28, 2017 — Genmab A/S (OMX: GEN) announced today that Janssen Research & Development, LLC, in collaboration with the European Myeloma Network (EMN) and Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), plans to start a Phase III study of daratumumab in relapsed and refractory multiple myeloma. The study (MMY3013, APOLLO) is a randomized Phase III that will compare daratumumab in combination with pomalidomide and dexamethasone versus pomalidomide and dexame
-
-
netop Bulder
-
M.h.t Triggerliste i resten af Q2. Så er det vel også interessant at se på de salgstal der kommer din og hvorvidt der er en eksponentiel udvikling i salget. Forhåbentligt vil det meget hurtigt vise, at Genmaps guidance er for konservativ :-).
-
Ja selvfølgelig.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind